Chief Executive Officer and Chairman
Dr. Galvin has been at the forefront of multi-disciplinary technology commercialization for more than 20 years. In 1993, he launched Kionix, Inc. to commercialize a novel MEMS technology platform. In 2000, Dr. Galvin successfully engineered the sale of Kionix's telecommunications platform to Calient Networks, Inc., retaining the consumer electronics, automotive and microfluidic opportunities presented by the original MEMS platform. In 2009, he successfully sold the second incarnation of Kionix, Inc. to Rohm Co., Ltd,. Prior to selling Kionix, Inc. to Rohm Dr. Galvin spun-out Rheonix, Inc. to capitalize on non-MEMS based microfluidic opportunities the molecular diagnostic industry.
Dr. Galvin is a member of several scientific societies; he has published over 20 technical papers and is an inventor of 58 patents. He is a member of the Cornell Board of Trustees, Advisory Council of the Cornell Engineering College and serves as a Director of the Boyce Thompson Institute for Plant Research, the KensaGroup, the El Portal de Belén Foundation and Ithaca's Sciencenter. Dr. Galvin holds a B.S. from the California Institute of Technology in electrical engineering and a Ph.D. in materials science and M.B.A. from Cornell University.
Prior to joining Rheonix, Inc., Mr. Eisenhut co-founded and was Managing Director of KensaGroup, a venture creation firm, where he originated and launched fourteen university-derived technology start-ups. He has served mid-market manufacturing companies in the capacities of CEO and COO, and was Vice President of a multi-billion-dollar international food retailer. Mr. Eisenhut has served on the boards of NovaSterilis, Inc, MedHesives, Inc, Prendismo, LLC, and Novomer, Inc. In addition to corporate boards, Mr. Eisenhut has served as an advisor to New York's Task Force on Economic Development and Emerging Industries, was a board member to the Center for Life Science Enterprise at Cornell University and currently serves on the Board of Directors of Cayuga Medical Center. Tony earned his B.S. from Cornell University.
Chief Scientific Officer and Senior Vice President of Research & Development
Dr. Zhou was Director of Microfluidics for Kionix, Inc., where he led the effort to develop the Company's microfluidic technologies, framed the microfluidic IP position for long-term growth and directed external collaborations. Prior to this, he was a Senior Research Investigator for Discovery Technology with Bristol-Myers Squibb Company in Princeton, NJ. There, he was engaged in developing new technologies for optimal drug discovery and development productivity. Dr. Zhou was a Group Leader for Automated Synthesis and Information Management with Sepracor Inc. of Marlborough, MA, where he established the Company's drug discovery infrastructure. As a Scientist at Arris Pharmaceuticals, he completed the proprietary PILOT™ technology development and used the platform for combinatorial library synthesis. Dr. Zhou received his Ph.D. and M.A., both in chemistry, from Columbia University and earned a B.S. in chemistry from Jilin University in China. He has published more than 20 papers and holds nine patents in the areas of combinatorial chemistry, drug discovery instrumentation and microfluidic chip fabrication and applications.
Chief Financial Officer and Vice President of Administration
Mr. Smith, CPA, joined Rheonix in October 2010 as Vice President of Administration and Chief Financial Officer. He brings with him 25 years of public and private industry experience in finance, accounting, and operations with both startups and high growth manufacturers. Prior to joining Rheonix, he served as Corporate Controller of Kionix, Inc. from its early development stage through its exponential growth, highlighted by the 2009 acquisition by Rohm Co. Ltd of Japan for $233M. During his tenure with Kionix, he was actively involved in the company’s financing; the spin-off of the company’s microfluidics division into Rheonix, Inc.; and the due diligence associated with the Rohm transaction. Prior to Kionix, Mr. Smith served as Chief Financial Officer and Director of Operations of Prolac, Inc., a medical products start-up. Mr. Smith holds a B.S. in Accounting from Le Moyne College and is a member of the American Institute of Certified Public Accountants.
Senior Vice President for Corporate Business Development and Scientific Affairs
Dr. Montagna was President of Innovative Biotechnologies International, Inc. prior to its acquisition by Rheonix, Inc. in 2008. Earlier, he served as Director of Biological Operations of Associated Biomedic Systems and President of Cellular Products. He has over 30 years of leadership experience and has managed the commercialization of over 40 biotechnology products. He has published 40 scientific papers and holds a number of patents in the biosensor area. He also holds an Adjunct Professorship in the Department of Biological and Environmental Engineering at Cornell University. Dr. Montagna earned a Ph.D. in molecular biology from the University of Buffalo and served post docs at NYU Medical Center as an NIH Fellow in Experimental Pathology and at the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, in the area of chemical carcinogenesis. In 1988, he testified before President Reagan's Presidential AIDS commission, providing data in support of a recommendation that the U.S. initiate mandatory screening of its donated blood supply for the presence of antibodies to HTLV-1, a human retrovirus related to the AIDS virus.
Vice President of IP and Licensing
Mr. Brenner joined Rheonix in July 2007. Prior to this, he was a Senior Technology Manager at Cornell University’s technology licensing office, CCTEC, where he managed commercialization of drug delivery, diagnostic devices, food science, and other analytical inventions developed by Cornell’s research faculty. Mr. Brenner was the founder and president of Aureus, Inc., specializing in financial and organizational solutions for technology-based companies. Mr. Brenner is a longtime member of the Licensing Executive’s Society and a Certified Licensing Professional. He holds a B.S. in Plant Science from the University of New Hampshire, an M.S. in Science Education from Syracuse University, and an M.B.A. from Cornell University.
Vice President of Marketing and Sales
Mr. Pemberton, a 16-year veteran in IVD sales, product marketing, and leadership positions, joined Rheonix in January 2013 as Vice President of Marketing and Sales. Prior to joining Rheonix, he served as the Corporate Account Director for Ventana Medical Systems, a member of the Roche Group, and was responsible for strategy, sales execution, business operations, and top line revenue for a global reference laboratory customer. Before Ventana Medical Systems, Mr. Pemberton held positions in sales and marketing with distinction at Abbott Diagnostics and Abbott Point of Care. Mr. Pemberton is a certified Medical Technologist and received his B.S. from Arizona State University.
Vice President of Manufacturing
Mr. Gill has more than 15 years of experience building operational and supply chain infrastructure for early-stage companies in the biotech, life science, and medical device fields. Most recently, he was Director, Reagent Manufacturing Operations at 454 Life Sciences, a division of the Roche Group. Prior to joining Roche, Mr. Gill held similar positions at early stage companies, Immunicon (now Veridex) and Songbird Hearing Inc., where he helped to build the manufacturing capabilities of both organizations. Mr. Gill is experienced in implementing cGMP and ISO 13485 certified manufacturing operations. Mr. Gill earned a bachelor’s degree from Albright College.